SCA Prep

Cancer and Palliative Care

Cancer recognition, two-week wait referrals, end of life care and symptom management.

Last reviewed

Use this quick reference guide to study and ensure you have mastered these common cases from the curriculum. You can generate specific cases on our SCA cases page or even practice them with our specialised and UK guidelines trained AI Actors.

1Lung Cancer: Recognition and 2-Week Wait

Lung cancer often presents late. A low threshold for investigation is crucial.

Urgent Chest X-ray (within 2 weeks)

Offer to patients >40 if they have:

  • • Persistent or recurrent chest infection.
  • • Finger clubbing.
  • • Supraclavicular lymphadenopathy.
  • • Chest signs consistent with lung cancer.
  • • Thrombocytosis (raised platelets).

2-Week Wait Referral

  • • Chest X-ray suggests lung cancer.
  • • Aged >40 with unexplained haemoptysis.

Safety Netting

A normal CXR does not completely rule out lung cancer. If suspicion remains high (e.g., persistent symptoms in a smoker), consider CT scanning or specialist referral.

2Bowel Cancer: Screening and Referral

The presentation can be subtle, from anaemia to change in bowel habit.

Visual explanation

Symptomatic FIT: referral and safety-netting

Rectal mass? Consider a suspected colorectal cancer referral directly. FIT is not a prerequisite.

Otherwise, offer symptomatic FIT when indicated

≥10 µg Hb/g faeces

Suspected cancer pathway referral

Below 10 or sample not returned

Actively safety-net: track results, help with sample return and agree reassessment for persistent symptoms.

Strong ongoing clinical concern? Do not delay referral to an appropriate secondary care pathway.

Remember: A low FIT is not a cancer exclusion test. Record who will review the result, what happens if no sample is returned, and when ongoing symptoms trigger reassessment. This diagram concerns symptomatic testing, not bowel screening.

Simplified teaching diagram. Sources: NICE NG12: colorectal cancer referral

When to Offer FIT and Refer (NICE NG12, 2023)

Offer a FIT test to adults with:

  • • A change in bowel habit, iron-deficiency anaemia, or an abdominal mass.
  • • Aged 40 and over with unexplained weight loss and abdominal pain.
  • • Aged 50 and over with unexplained rectal bleeding, abdominal pain or weight loss.
  • • Aged under 50 with rectal bleeding and either abdominal pain or weight loss.
  • • Aged 60 and over with anaemia, even without iron deficiency.

A FIT result of 10 micrograms Hb/g or more means an urgent suspected cancer (2-week wait) referral. A rectal mass doesn't need a FIT first: consider referral straight away.

FIT Testing (Faecal Immunochemical Test)

Since 2023, FIT guides referral for most people with lower GI symptoms, not just lower-risk ones. If the result is below 10, or the sample isn't returned, safety-net, and don't delay referral if clinical concern is strong.

Note: FIT is for symptomatic patients in this context, distinct from the national screening programme (for people without symptoms).

3Prostate Cancer: PSA Testing and Counselling

There is no national screening programme, but men can request a PSA test.

Counselling

Before testing, men should be counselled on the pros and cons (false positives, over-diagnosis of indolent cancers, side effects of biopsy/treatment).

Referral Criteria (2-Week Wait)

  • • Prostate feels malignant on DRE (hard, irregular).
  • • PSA levels are above the age-specific reference range.

Age-Specific PSA Ranges

  • • 40-49: >2.5
  • • 50-59: >3.5
  • • 60-69: >4.5
  • • 70-79: >6.5

Factors Affecting PSA

  • • UTI (wait 1 month)
  • • Ejaculation (wait 48 hours)
  • • Vigorous exercise (wait 48 hours)
  • • DRE can cause a minor rise but usually not clinically significant enough to delay testing if cancer suspicion is high.

4Breast Cancer: Lumps and Pain

Most breast lumps are benign, but rapid exclusion of cancer is essential.

2-Week Wait Referral

  • • Aged >30 with an unexplained breast lump (with or without pain).
  • • Aged >50 with unilateral nipple changes (discharge, retraction).
  • • Skin changes suggesting cancer (peau d'orange) or axillary lump >30.

Breast Pain (Mastalgia)

Alone, this is rarely a sign of cancer. If no lump/changes, manage conservatively (well-fitting bra, topical NSAIDs). Refer if intractable or focal.

Non-urgent

Women <30 with a lump (often fibroadenoma) still generally require referral but may not meet the 2-week criteria depending on local pathways.

5Ovarian Cancer: Non-specific Symptoms

Symptoms are often vague (bloating, IBS-like) leading to late diagnosis.

Trigger for Testing

Persistent or frequent (>12 times/month) symptoms of:

  • • Abdominal distension/bloating.
  • • Early satiety/loss of appetite.
  • • Pelvic/abdominal pain.
  • • Urinary urgency/frequency (new onset).

Investigation Pathway

  • CA125 Blood Test: First-line.
  • Ultrasound (Pelvis/Abdomen): If CA125 is raised.
  • Referral: If Ultrasound suggests cancer (or if clinical suspicion remains high despite normal scan).

Note: IBS rarely presents for the first time in women >50. Always screen for ovarian cancer.

6Palliative Care: The Gold Standards Framework

Palliative care is about identifying patients early to improve quality of life, not just terminal care.

Identification: The "Surprise Question"

"Would you be surprised if this patient died in the next 12 months?" If "No", add to the Palliative Care Register.

Advanced Care Planning (ACP)

Discuss preferences early:

  • • ReSPECT forms / DNACPR: Decisions on CPR and ceiling of treatment.
  • • Preferred Place of Care/Death: Home, Hospice, Hospital.

Co-ordination

Regular GSF meetings (MDT with district nurses, palliative care team) to review patients, symptom control, and anticipatory needs.

7Pain Management in Palliative Care

The aim is continuous pain relief.

Visual explanation

Palliative pain: breakthrough versus background control

1 · Breakthrough pain

More pain ↑

Short breakthrough episode on controlled background painA brief high peak interrupts a low, otherwise controlled baseline. A trigger such as movement may be present. Illustrative traces, not patient measurements.

Time →

Background pain is mostly controlled. Identify triggers, review rescue response and consider a plan for predictable movement-related pain.

2 · Uncontrolled background pain

More pain ↑

Persistently uncontrolled background painPain remains high across the observation period, without returning to a controlled baseline. Illustrative traces, not patient measurements.

Time →

Reassess the cause, regular analgesia, adherence and rescue use. Repeated rescue doses alone may not address the underlying problem.

Pain with new sedation, delirium or myoclonus? Consider opioid toxicity, renal deterioration and other causes. Seek urgent clinical advice; escalating the opioid may worsen harm. Respiratory depression needs an emergency response.

Remember: Review benefit and adverse effects together. A pain diary, timing of doses and the effect of rescue medication help distinguish short episodes from poor background control. These traces illustrate patterns; they are not a dose-conversion guide.

Simplified teaching diagram. Sources: Scottish Palliative Care Guidelines: pain management · NICE CG140: opioid review and adverse effects

Analgesic Ladder

Non-opioids (Paracetamol/NSAIDs) → Weak Opioids (Codeine) → Strong Opioids (Morphine).

Starting Strong Opioids

  • Morphine Sulfate (Immediate Release - e.g., Oramorph): For dose titration and breakthrough pain. Start 2.5-5mg every 4 hours.
  • Morphine Sulfate (Modified Release - e.g., Zomorph/MST): Once stable total daily requirement is known, convert to 12-hourly MR preparation.
  • Breakthrough Dose: Usually 1/6th of the total daily dose.

Toxicity

Signs include myoclonic jerks, confusion, hallucinations, respiratory depression. Check renal function (metabolites accumulate). Consider switching to Oxycodone or Alfentanil (safer in renal failure).

8Nausea and Vomiting in Palliative Care

Choose the anti-emetic based on the likely cause.

Gastric Stasis/Squashed Stomach

(e.g., hepatomegaly/ascites) → Metoclopramide or Domperidone (Prokinetics). Avoid in complete bowel obstruction (colic risk).

Chemical/Metabolic

(e.g., opioids, hypercalcaemia, renal failure) → Haloperidol or Levomepromazine.

Intracranial Pressure

→ Cyclizine or Dexamethasone.

Vestibular/Motion

→ Cyclizine.

Broad Spectrum

Levomepromazine is useful if the cause is unclear or multi-factorial.

9Breathlessness and Secretions

Distressing symptoms common at the end of life.

Breathlessness

  • Non-drug: Fan therapy (cool air on face), positioning (sit upright), anxiety management.
  • Medical: Low dose Oral Morphine (e.g., 2.5mg) reduces respiratory drive and anxiety. Benzodiazepines (e.g., Lorazepam/Midazolam) for associated panic.

Respiratory Secretions ("Death Rattle")

Noisy breathing caused by pooled secretions in the pharynx.

  • Explanation: Reassure family the patient is unlikely to be distressed by it.
  • Medication: Anticholinergics inhibit secretion production (but don't clear existing ones). Hyoscine Butylbromide (Buscopan) or Glycopyrronium are commonly used subcutaneously.

10Anticipatory Prescribing and End of Life

Ensuring medication is available in the home before it is needed to prevent crisis.

Just in Case (JIC) Box

Prescribe subcutaneous medications for the 4 common end-of-life symptoms:

  • • Pain: Morphine or Diamorphine.
  • • Nausea/Vomiting: Haloperidol, Levomepromazine, or Cyclizine.
  • • Agitation/Restlessness: Midazolam.
  • • Respiratory Secretions: Hyoscine Butylbromide or Glycopyrronium.

Syringe Drivers

Continuous Subcutaneous Infusion (CSCI) used when the oral route is no longer possible (dysphagia, weakness, unconsciousness) or for stable symptom control.

Verification of Death

Know the procedure for verifying death in the community and issuing the Medical Certificate of Cause of Death (MCCD). In expected deaths, police/coroner do not usually need to be informed.